Agenus shared on their LinkedIn page:
“At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab (BOT/BAL) combination in relapsed/refractory sarcoma, which showed durable responses across multiple subtypes. The results reinforce the potential of BOT/BAL in multiple cold, treatment-resistant solid tumors. Learn more here.”
Source: Agenus/LinkedIn